BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
Key Highlights
- ➤BriaCell presents four preclinical immunotherapy studies at SITC 2026.
- ➤Bria-OTS+ activated immune cells and killed tumor cells across three cancer models.
- ➤BP-80 showed a 50 mg/kg/day NOEL in cynomolgus monkeys.
- ➤TILsRx-001 antagonized PD-L1 immune inhibition in B7-H3-expressing cells.
- ➤CD80 variant achieved more than 130-fold stronger PD-L1 binding than wild-type.
Expert Statements
Miguel A. Lopez-Lago, PhD, Chief Scientific Officer of BriaCell
“The Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing in laboratory models spanning breast, prostate and lung cancers.”
Miguel A. Lopez-Lago, PhD, Chief Scientific Officer of BriaCell
“These findings support continued investigation of the platform, including how its immune responses may translate into clinical activity, potentially providing more durable and effective cancer immunotherapies.”
William V. Williams, MD, President and CEO of BriaCell
“The four presentations provide additional preclinical data supporting our cellular and protein-based immunotherapy research.”
William V. Williams, MD, President and CEO of BriaCell
“We are advancing the clinical evaluation of our Bria-OTS+ programs while continuing preclinical development of BriaPro’s candidates.”
* Four presentations highlight BriaCell’s Bria-OTS+™ cellular immunotherapy platform and BriaPro’s CD80-based immunotherapy programs * In vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing across breast, prostate and lung cancer models * BriaPro data describes BP-80 tolerability in nonhuman primates and engineered CD80 constructs with enhanced PD-L1 binding PHILADELPHIA and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced four preclinical research presentations at the Society for Immunotherapy of Cancer (SITC) 41(th) Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.
Get started
Create a free account to read the full story.